Ribozymes targeted to human CCR5 mRNA

Details Ribozymes targeted to human CCR5 mRNA Ribozymes targeted to human CCR5 mRNA

1998-03-11

2000-08-08

LeGuyader, John L.

Chemistry: molecular biology and microbiology

Vector, per se

435 6, 435 9131, 435375, 435455, 536 231, 536 232, 536 2431, 536 2433, 536 245, C07H 2104, C12Q 168, C12H 1500

Patent

active

061000876

ABSTRACT:
This invention provides ribozymes and combinations thereof, to cleave RNA sequences. The invention also provides a method of treating HIV-1 by down-regulating the CCR5 receptor.

REFERENCES:
patent: 5496698 (1996-03-01), Draper et al.
patent: 5525468 (1996-06-01), McSwiggen
Branch TIBS 23:45-50, Feb. 1998.
Flanagen Nature Biotechnology 17:48-52, 1999.
Crooke, Ch 1 of Antisense Research & Applications, Springch, 1998, pp. 2-50.
Guignerd et al. J. of Immunology 160:985-992, Jan. 1998.
Combadiere et al. J. of Leukocyte Biology 60:147-152 (1996).
Bauer, G. et al., "Inhibition of Human Immunodeficiency Virus-1 (HIV-1) Replication after Transduction of Granulocyte Colony Stimulating Factor-mobilized CD34+ Cells from Hiv-1 Infected Donors Using Retroviral Vectors Containing Anti-HIV-1 Genes," Blood, vol. 89, Apr. 1, 1997, pp. 2259-2267.
Bertrand, E. et al., "The Expression Cassette Determines the Functional Activity of Ribozymes in Mammalian Cells by Controlling Their Intracellular Localization," RNA, vol. 3(1), 1997, pp. 75-88.
Taylor, N. R. et al., "Chimeric DNA-RNA Hammerhead Ribozymes Have Enhanced in vitro Catalytic Efficiency and Increased Stability in vivo," Nucleic Acids Research, vol. 20(17), Sep. 11, 1992, pp. 4559-4565.
Good, P. D. et al., "Expression of Small, Therapeutic RNAs in Human Cell Nuclei," Gene Therapy, vol. 4(1), 1997, pp. 45-54.
Rossi, J. J. et al., "Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems", Aids Research and Human Retroviruses, vol. 8(2), Feb. 1, 1992, pp. 183-189.
Gonzalez, M. et al., "A Hammerhead Ribozyme Targeted to the Human Chemokine Receptor CCR5", Biochemical and Biophysical Research Communications, vol. 251, Oct. 20, 1998, pp. 592-596.
Huang, Y. et al., "The role of a mutant CCR5 allele in HIV-1 transmission and disease progression", Nature Medicine, vol. 2, No. 11, Nov. 1996, pp. 1240-1243.
Liu, R. et al., "Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection", Cells, vol. 86, Aug. 9, 1996, pp. 367-377.
Samson, M. et al., "Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene", Nature, vol. 382, Aug. 22, 1996, pp. 722-725.
Dragic, T. et al., "HIV-1 entry into CD4.sup.+ cells is mediated by the chemokine receptor CC-CKR-5", Nature, vol. 381, Jun. 20, 1996, pp. 667-673.
Dean, M. et al., "Genetic Restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene", Science, vol. 273, Sep. 27, 1996, pp. 1856-1862.
Deng, H. et al., "Identification of a major co-receptor for primary isolates of HIV-1", Nature, vol. 381, Jun. 20, 1996, pp. 661-666.

Affiliated with

Also associated with

Rating

Ribozymes targeted to human CCR5 mRNA does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ribozymes targeted to human CCR5 mRNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ribozymes targeted to human CCR5 mRNA will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1149182